FDA Deputy Commissioner for Policy Michael Taylor met with Pharmaceutical Manufacturers Association officials on April 15 to review the agency's revised concept paper on industry-supported continuing medical education. PMA views the current draft as greatly improved over earlier drafts. FDA is doing its political spadework this time, carefully previewing its modified CME policy with interested parties, including HHS and the Office of Management and Budget, before it is issued....
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth